

1995-2014

<25 patients

2015-2020

>25 patients


2021-2024

>50 patients

year	# patients	# sites and location
<b>2009</b>	<b>65</b>	multi, N. America
<b>2014</b>	<b>40</b>	single, Canada
2015	66	multi, France
<b>2016</b>	<b>293</b>	multi (45), N. America
<b>2017</b>	<b>105</b>	multi (22), N. America
2017	22	single, USA
2019	39	multi (11), Türkiye
2019	49	multi (1,700), Japan
<b>2021</b>	<b>85</b>	multi, Canada/Italy
2021	34	single, China
2022	48	single, China
<b>2022</b>	<b>131</b>	multi, N. America
2022	61	single, China
2023	46	multi (14), France
2023	337	multi, 41 countries
2024	17	single, USA
<b>2024</b>	<b>398</b>	multi, N. America
2024	179	multi (17), China
<b>2025</b>	<b>145</b>	multi, N. America

We have described  
~1/3 of the ~1,500  
cases of childhood  
chronic, systemic  
vasculitis reported  
globally

If all your blood  
vessels were  
arranged in a single  
line, how far would  
they stretch?






96,500 – 160,000 km!

2.4 – 4 times the  
earth's circumference

~1/3 of the way to the  
moon




Small sized blood vessels are predominantly affected in childhood vasculitis, most frequently in the kidneys



Bernardi et al Nephrol Dial Transplant 2023 38:66-69

Story #1  
See today. Predict tomorrow.








Image from Mayo Foundation for Medical Education and Research

*Glomeruli* are networks of tiny blood vessels and the main filtering unit of the kidneys.


*Glomerulonephritis* is inflammation of the glomeruli.

# Vasculitis-associated Glomerulonephritis


Healthy

Crescentic


Sclerotic



> 50%  
good prognosis



> 50%  
unpredictable  
active (treatable) disease



> 50%  
poor prognosis  
permanent damage

Progression to  
end stage kidney  
disease can be  
rapid (weeks).

*All* patients get  
aggressive immune  
suppressive  
therapy at  
diagnosis

Goal is to  
recover or at  
least preserve  
existing kidney  
function



# Vasculitis in the kidneys

**62%**

Have <60% normal  
kidney function

**25%**

Kidney failure



**Diagnosis**

**42%**

Permanent  
damage




**26%**

Uncontrolled  
disease




**80%**



**1 year**

# Vasculitis in the kidneys





**Andreas Kronbichler** @AKronbichler · Jun 18, 2024

Another reason why ANCA-GN research is so important; children with MPO-ANCA vasculitis seem to have a better kidney function recovery than those with PR3-ANCA vasculitis. This is the other way around in adults!

Recent article in @bmj\_rmdopen rmdopen.bmj.com/content/10/2/e...



### Kidney Outcomes in Pediatric ANCA-Associated Vasculitis

<https://doi.org/10.62716/kn.000292025>

One year after diagnosis, most patients with pediatric-onset antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have inactive kidney disease, but nearly half have evidence of kidney damage, reports a study in *Arthritis & Rheumatology*.

Using data from ARChive (A Registry of Childhood Vasculitis), the researchers identified 145 patients diagnosed with granulomatosis with polyangiitis, microscopic polyangiitis, or ANCA-positive pauci-immune glomerulonephritis. All were 18 years or younger at diagnosis, had kidney disease based on biopsy or dialysis dependence, and had clinical data at diagnosis and at a 12- or 24-month follow-up.

Rates of inactive kidney disease, defined as a pediatric vasculitis activity score of 0 or 1, were compared at 12 or 24 months. Improvements in kidney function and evidence of kidney damage were assessed at 24 months. The study also evaluated the prognostic implications of initial kidney function, based on estimated glomerular filtration rate (eGFR) and Kidney Disease: Improving Global Outcomes (KDIGO) stage.

Sixty-eight percent of patients were female; the median age at baseline was 13.8 years. The diagnosis was granulomatosis with polyangiitis in 78% of patients. Seventy-one percent of patients initially had less than normal kidney function, and 25% were on dialysis. At 12 months, 83% of patients with available data were classified as having inactive kidney disease. By 24 months, this figure increased to 98%.

However, 42% of patients had evidence of permanent kidney damage at 12 months. Findings included an eGFR

of 15 to 60 mL/min/1.73 m<sup>2</sup> in 31% of patients, kidney failure with an eGFR less than 15 mL/min/1.73 m<sup>2</sup> in 21%, and hypertension over the 95th percentile or antihypertensive medication in 15%.

The baseline KDIGO category showed a linear association with follow-up outcomes. Odds ratios for a non-normal KDIGO category at 12 months were 4.77 for moderately reduced kidney function, 8.62 for severely reduced kidney function, and 26.3 for kidney failure at baseline. An eGFR of 38 mL/min/1.73 m<sup>2</sup> appeared to be the optimal cutoff for identifying patients at risk of moderate to severely reduced kidney function.

Pediatric-onset AAV is a rare, relapsing disease, with blood vessel damage potentially leading to downstream involvement of the kidneys and other organ systems. The new study adds to previous evidence of early kidney damage, even with aggressive treatment.

The extent of reduction in kidney function at baseline may provide a simple and practical tool for outcome prediction in pediatric AAV. "Providing improved, individualized insights into anticipated outcomes will ultimately allow patients and their families to be more involved in shaping and participating in their own care," the investigators conclude [Toor KK, et al.; PedVas Investigators Network. Evaluating renal disease in pediatric-onset antineutrophil cytoplasmic antibody-associated vasculitis: Disease course, outcomes, and predictors of outcome. *Arthritis Rheumatol*, published online December 3, 2024. doi: 10.1002/art.43071]. ■



"If we can predict from an early stage how a child's disease will behave and how it will respond to treatment, then we can better tailor treatment."

Kimberly A. Morishita, MD, MHSc




**Andreas Kronbichler**  
@AKronbichler

Please find our Editorial discussing key differences between pediatric and adult ANCA-GN in @bmj\_rmdopen!

[rmdopen.bmj.com/content/10/3/e...](https://rmdopen.bmj.com/content/10/3/e...)

Together with @louise oni and Dr. Barnini! Interesting aspects clearly highlighting huge differences ...





The challenge is in knowing - at diagnosis - which child will have

- milder disease
- severe yet treatable disease
- damage beyond repair







Image from iStock by Getty Images


*Estimated glomerular filtration rate (eGFR) is the rate (mL / min / 1.73m<sup>2</sup>) that blood is filtered through the glomeruli.*

*It is a biomarker of kidney function.*

# The need for Prognostic Biomarkers








@ diagnosis  
normal function  
healthy glomeruli

Did they maintain function because of  
the aggressive treatment?



@ diagnosis  
kidney failure  
crescentic glomeruli

Why did they not respond to treatment  
and need a transplant within 4 months?

## Prognostic Biomarker Discovery

